The prevalence of neurodegenerative disease (ND) is increasing, partly owing to extensions
in lifespan, with a larger percentage of members living to an older age, but the ND aetiology …

The central nervous system is characterized by a high content of sphingolipids and by a high
diversity in terms of different structures. Stage-and cell-specific sphingolipid metabolism and …

The family of sphingosine-1-phosphate receptors (S1PRs) are G protein-coupled and
comprise of five subtypes, S1P 1-S1P 5. These receptors are activated by the sphingolipid …

Research interest in a non-protein amino acid β-N-methylamino-L-alanine (BMAA) arose
due to the discovery of a connection between exposure to BMAA and the occurrence of …

The implication of the cyanotoxin β-N-methylamino-l-alanine (BMAA) in long-lasting
neurodegenerative disorders is still a matter of controversy. It has been alleged that chronic …

The non-protein amino acid β-methylamino-L-alanine (BMAA) is a neurotoxin present in
microalgae and shown to accumulate in the food web. BMAA has been linked to the …

Mesenchymal stromal cells (MSCs) have been shown to have useful properties for cell
therapy and have been proposed for treatment of neurodegenerative diseases, including …

The cyanobacterial non-protein amino acid α-amino-β-methylaminopropionic acid, more
commonly known as BMAA, was first discovered in the seeds of the ancient gymnosperm …

During the last two decades the study of the sphingolipid anabolic, catabolic, and signaling
pathways has attracted enormous interest. Especially the introduction of fingolimod into …

Sphingosine 1-phosphate (S1P) is extensively researched as a lysophospholipid and is
crucial in various physiological and pathological processes. It achieves this via signalling …